My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2016
PATIENT CARE AND SCIENCE
IDSA Partners with AGA on New Registry to Track Fecal Microbiota Transplants

IDSA is partnering with the American Gastroenterological Association (AGA) in a new initiative to develop the first national registry for short- and long-term patient outcomes associated with fecal microbiota transplantation (FMT).

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is funding the new initiative, which will enable researchers to identify potential adverse outcomes and possible safety concerns of FMT.

Rapidly accumulating evidence suggests that modifying gut microbiota may promote health or treat disease, with FMT for Clostridium difficile infection being the first successful clinical application of this concept. Researchers are now exploring FMT for conditions beyond C. difficile.  However, the early adoption and expansion of FMT in clinical practice has outpaced scientific study, resulting in a lack of understanding of the potential health risks from humantohuman transfer of stool. Eventually, the data collected through the registry will provide long-term uses in understanding how manipulation of the gut microbiota could treat disease and promote overall health.

Additional partners in the initiative are the Crohn’s and Colitis Foundation of America and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. 

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Updated IDSA Guideline on Valley Fever Published in CID
Drug-Susceptible Tuberculosis Guidelines Now Available
Updated Guideline on Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia Now Available
HCV Guidance Website Updated to Reflect Latest Drug Developments
IDSA Partners with AGA on New Registry to Track Fecal Microbiota Transplants
CLSI Updates on Antimicrobial Susceptibility Testing Are Now Available
CDC Issues Travel Warning for Area in Miami Due to Locally Transmitted Zika Virus; Generic Version of Tamiflu Approved by FDA
CLINICAL PRACTICE MANAGEMENT
Virtual Supervision of “Incident To” Services
POLICY AND ADVOCACY
Take 3 Minutes to Tell the UN to Take Global Action on Antimicrobial Resistance
As US Cases Mount, IDSA Continues To Push for Zika Funding
Massachusetts Passes Troubling Lyme Legislation
Party Platforms Include IDSA Priorities
GLOBAL HEALTH
Live from Durban: Science Speaks Covers AIDS 2016
EDUCATION AND RESOURCES
Stipends Available to ID Medical Student Interest Groups
Vaccines Virtual Collection from CID
Upcoming Webinar on Antibiotic Drug Development
YOU AND YOUR COLLEAGUES
IDSA, HIVMA Seek Clinical Practice Guidelines Editor
FROM THE PRESIDENT
IDSA Advocacy on ID-Led Stewardship—More Progress on our Strategic Priorities
TOP STORIES
Don’t Miss These IDSA Guidelines Updates
IDSA Honors 111 Distinguished Physicians, Scientists with FIDSA
IDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika Outbreak
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.